VITAS Banks on Length of Stay, Referral Mix Management

Why It Matters

The approach shows how managing referral sources and stay length can mitigate Medicare cap risk and boost profitability, offering a replicable blueprint for the hospice sector.

Key Takeaways

• Hospital referrals now 43.8% of admissions, hitting target range
• Florida cap liability eliminated; Q1 2026 cap $0 in state
• Q1 revenue up 3.1% to $420 million, admissions +6.9%
• Average length of stay fell to 102.7 days from 118.7
• Labor costs stayed below budget while accelerating non‑hospital admissions

Pulse Analysis

Medicare’s per‑beneficiary cap on hospice payments has long been a pressure point for providers that rely heavily on short‑stay patients. When a large share of admissions comes from home‑based or assisted‑living sources, the average length of stay can balloon, pushing reimbursements toward the cap and eroding margins. VITAS Healthcare, the nation’s largest for‑profit hospice, tackled this challenge by deliberately increasing the proportion of hospital‑directed referrals, which tend to generate shorter stays and more predictable billing. The shift paid off quickly, allowing the company to wipe out its Florida cap liability in the first quarter of 2026.

The operational tweak produced measurable financial gains. 2% to 22,723. 8% of all admissions—squarely within VITAS’s 42‑45% target range. At the same time, labor expenses stayed under budget, reinforcing the profitability of the new mix.

VITAS’s experience illustrates how strategic referral management can neutralize cap exposure while sustaining growth, a lesson that other hospice operators are likely to emulate. By balancing short‑stay hospital cases with longer‑stay community admissions, providers can smooth revenue streams and protect against regulatory headwinds. Investors will watch whether the model scales beyond Florida, especially in high‑cost markets like California where VITAS still reports modest cap accruals. If the company maintains its disciplined mix, the outlook points to continued top‑line expansion and stronger cash generation in an increasingly competitive hospice landscape.